Eneirys Perez Castillo

Structured Laboratory Technician offering background in collecting, processing and analyzing various specimens. Familiar with basic medical terminology, laboratory protocols and testing procedures. Expertise in urinalysis and blood typing. Recognized for performing laboratory tests and procedures with attention to detail, optimum quality and expedience.

• 01/01/2022, 07/01/2022, Nasalferon, Interferon alfa 2b for nasal application for the prophylaxis of SARS-CoV-2 virus infection, Cuba
• 03/01/2021, 05/01/2022, Mambisa, Anti-COVID-19 vaccine candidate, nasal application, Cuba
• 06/01/2021, 08/01/2022, Purify the so-called n protein of the virus, the nucleocapsid, the most abundant After three months, they generated monoclonal antibodies, of high demand, and obtained a diagnostic test in the form of a rapid strip at the laboratory level, Cuba
• 03/01/2021, 04/01/2021, A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults with Respiratory Distress due to COVID-19
• 03/01/2021, 04/01/2021, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease. Phase III
• 09/01/2020, present, Conclusion of the development and validation of the Elisa system for the detection of unwanted immunogenicity of the epidermal growth factor and yeast contaminants of Herberprot-P, conditioning tests for the introduction of this product in prime markets world, Cuba
• 11/01/2020, 06/01/2022, Quimi-HibVaccine against diseases caused by Haemophilus influenzae type
• 04/01/2021, 04/01/2021, An Interventional Efficacy and Safety, Phase 2/3, Double-Blind, 2-Arm Study to Investigate orally administered PF-07321332/Ritonavir compared with placebo in nonhospitalized symptomatic adults participants with COVID-19 who are at low risk of progressing to severe illness
• 01/01/2021, 04/01/2021, A Randomized, Double Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101(Dihydroergotamine Nasal Power) in the Acute Treatment of Migraine. Phase II
• 12/01/2020, 04/01/2021, A Phase 2B Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adults Outpatients with respiratory Syncytial Virus (RSV) Infection who are at High Risk for RSV-related Disease Progression
• 11/01/2020, present, Obtaining the Sanitary Registry of the dietary supplement Fructooligosaccharides Syrup (FOS) for human consumption, as well as its introduction in the formulation of functional foods and nutraceuticals of national production based on the technology developed and patented in the center, climbing at the Sorbitol plant in Camagüey, Cuba
• 11/01/2020, 04/01/2021, Clinical Rater administering various psychometric efficacy scales, as well as completing interviews/ratings on study participants specific to several study protocols (ADCS-CGIC, CDR, C-SSRS, MHIS, NPI), Cuba
• 08/01/2020, 12/01/2021, HeberFast Line anti-transglutaminansaTest for early diagnosis of celiac disease, Cuba
• 12/01/2019, 07/01/2020, Multi-Target stool DNA (mt-sDNA) test, Cologard 2.0 for colorectal cancer screening
• 11/01/2019, 11/01/2020, Acute Treatment Trial in Adults with Migraines, Phase II/III
• 09/01/2019, 07/01/2021, Hypertension incidents in Adolescentes, Cuba
• 08/01/2019, 11/01/2020, Phase 2 Study in Obese Subjects with NAFLD/NASH, Cuba
• 07/01/2019, 11/01/2020, A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of efficacy and safety of Solanezumab versus placebo in Prodromal Alzheimer's Disease
• 03/01/2019, 11/01/2020, Randomized, Double-Blind, Placebo Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis, Phase III
• 01/01/2019, 02/01/2020, A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)